Home › Companies › Theravance Biopharma, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Theravance Biopharma, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 12, 2026: 8 items on Theravance Biopharma, Inc.’s Form 8-K, filed June 12, 2026: 6 elected · 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Theravance Biopharma, Inc. in the interactive database Compare manager voting policies
These tallies are Theravance Biopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Laurie Smaldone Alsup | 42,725,649 | 124,187 | 53,867 | -- | 4,156,175 | 99.7% | Elected | — |
| Elect Director: Susannah Gray | 42,231,530 | 618,306 | 53,867 | -- | 4,156,175 | 99% | Elected | — |
| Elect Director: Dean J. Mitchell | 42,557,257 | 297,316 | 49,130 | -- | 4,156,175 | 99.3% | Elected | — |
| Elect Director: Donal O'Connor | 42,535,463 | 319,110 | 49,130 | -- | 4,156,175 | 99.3% | Elected | — |
| Elect Director: Deepika R. Pakianathan | 41,936,019 | 918,543 | 49,141 | -- | 4,156,175 | 98% | Elected | — |
| Elect Director: Rick E Winningham | 42,474,538 | 377,274 | 51,891 | -- | 4,156,175 | 99.1% | Elected | — |
| Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 46,471,340 | 572,896 | 15,642 | -- | -- | 99% | Approved | — |
| Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers | 42,631,324 | 221,196 | 51,183 | -- | 4,156,175 | 99.5% | Approved | — |
Source: Theravance Biopharma, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
214 asset managers disclosed a vote on at least one Theravance Biopharma, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Dean J. Mitchell
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Dean J. Mitchell”): 42,557,257 for, 297,316 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 8,429,312 for, 7,544 against, 11,536 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,161,406 | 3,444 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 213,560 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,325 | 0 | 0 | 0 | For |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Deepika R. Pakianathan
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Deepika R. Pakianathan”): 41,936,019 for, 918,543 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 8,188,650 for, 248,206 against, 11,536 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,161,404 | 3,446 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 0 | 213,560 | 0 | 0 | Against |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,325 | 26,000 | 0 | 0 | Mixed |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Prior year: 99.5% for (May 19, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Donal O'Connor
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Donal O'Connor”): 42,535,463 for, 319,110 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 8,431,518 for, 5,337 against, 11,536 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,159,728 | 5,121 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 213,560 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,325 | 0 | 0 | 0 | For |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Laurie Smaldone Alsup
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Laurie Smaldone Alsup”): 42,725,649 for, 124,187 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 8,430,122 for, 6,734 against, 11,536 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,161,406 | 3,444 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 213,560 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,325 | 0 | 0 | 0 | For |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Prior year: 93.6% for (May 19, 2025 meeting) ▲ 5.6 pts
Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Rick E Winningham
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Rick E Winningham”): 42,474,538 for, 377,274 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 8,433,196 for, 3,660 against, 11,536 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,161,406 | 3,444 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 213,560 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,325 | 0 | 0 | 0 | For |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 99.7% for (May 19, 2025 meeting) ▼ 1.2 pts
Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Susannah Gray
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Susannah Gray”): 42,231,530 for, 618,306 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 8,226,395 for, 210,461 against, 11,536 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,163,172 | 1,678 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 213,560 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 208,783 | 0 | 0 | Against |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,325 | 0 | 0 | 0 | For |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.5% Approved · of votes cast
Description as filed by funds: Approve the non-binding advisory resolution regarding the compensation of our named executive officers.
Theravance Biopharma, Inc.’s own tally for this item (“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:”): 42,631,324 for, 221,196 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,164,850 | 0 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 213,560 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,325 | 0 | 0 | 0 | For |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Fund voting reports, all 68 managers: 8,438,740 for, 11,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 8,944,605 | 0 | 0 | 0 | For |
| Newtyn Management, LLC | 4,036,218 | 0 | 0 | 0 | For |
| Irenic Capital Management LP | 2,566,196 | 0 | 0 | 0 | For |
| BlackRock | 1,599,391 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 965,125 | 0 | 0 | 0 | For |
| Weiss Asset Management LP | 765,611 | 0 | 0 | 0 | For |
| State Street | 729,423 | 6,939 | 0 | 0 | For |
| Janus Henderson | 719,632 | 0 | 0 | 0 | For |
| DE Shaw | 673,382 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 558,077 | 0 | 0 | 0 | For |
| Two Sigma | 454,831 | 0 | 0 | 0 | For |
| Vanguard | 314,531 | 0 | 0 | 0 | For |
| Charles Schwab | 310,998 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 250,000 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 248,682 | 0 | 0 | 0 | For |
| Northern Trust | 208,574 | 1,556 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 208,783 | 0 | 0 | 0 | For |
| SEI | 200,074 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 185,456 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 167,102 | 0 | 0 | 0 | For |
| Fidelity | 123,886 | 0 | 0 | 0 | For |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 123,582 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| T. Rowe Price | 112,626 | 0 | 0 | 0 | For |
| Prudential/PGIM | 104,682 | 2,600 | 0 | 0 | For |
Institutional-manager reports, all 166 managers: 26,433,247 for, 99,669 against, 1,741 abstained, 1,214 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Theravance Biopharma, Inc.’s own tally for this item (“Proposal 2: Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified”): 46,471,340 for, 572,896 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 8,432,892 for, 6,401 against, 11,536 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,164,849 | 1 | 0 | 0 | For |
| BlackRock | 2,060,691 | 0 | 0 | 0 | For |
| Fidelity | 972,682 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 350,637 | 0 | 0 | 0 | For |
| Charles Schwab | 309,563 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 292,586 | 0 | 0 | 0 | For |
| Invesco | 237,758 | 0 | 0 | 0 | For |
| Dimensional | 231,199 | 0 | 0 | 0 | For |
| State Street | 213,560 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| SEI | 198,532 | 0 | 0 | 0 | For |
| American Century | 117,902 | 0 | 0 | 0 | For |
| Equitable | 112,903 | 0 | 0 | 0 | For |
| TIAA | 88,351 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,103 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,547 | 0 | 0 | 0 | For |
| EA Series Trust | 55,127 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,440 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,325 | 0 | 0 | 0 | For |
| Legg Mason | 47,355 | 0 | 0 | 0 | For |
| Global X | 42,704 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 42,704 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 41,256 | 0 | 0 | 0 | For |
| Prudential/PGIM | 34,180 | 0 | 0 | 0 | For |
| Northern Trust | 33,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,515,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.20% |
| 2 | BlackRock | 4.00% |
| 3 | Fidelity | 1.89% |
| 4 | Janus Detroit Street Trust | 0.68% |
| 5 | Charles Schwab | 0.60% |
| 6 | Pacer Funds Trust | 0.57% |
| 7 | Invesco | 0.46% |
| 8 | Dimensional | 0.45% |
| 9 | State Street | 0.41% |
| 10 | Delaware/Macquarie | 0.41% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Madison Avenue Partners, LP | 17.36% |
| 2 | Newtyn Management, LLC | 7.84% |
| 3 | Irenic Capital Management LP | 4.98% |
| 4 | BlackRock | 3.10% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.87% |
| 6 | Weiss Asset Management LP | 1.49% |
| 7 | State Street | 1.43% |
| 8 | Janus Henderson | 1.40% |
| 9 | DE Shaw | 1.31% |
| 10 | ACADIAN ASSET MANAGEMENT LLC | 1.08% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Madison Avenue Partners, LP | 9,511,150 | 18.46% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| Madison Avenue International LP | 9,212,252 | 17.88% | Schedule 13G, filed August 14, 2026 |
| Weiss Asset Management LP | 7,457,060 | 14.48% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| BlackRock | 4,296,290 | 8.34% | Form 13F, quarter ended March 31, 2026 |
| Newtyn Management, LLC | 3,434,191 | 6.67% | Schedule 13G, filed August 14, 2026 |
| Irenic Capital Management LP | 2,760,948 | 5.36% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| Vanguard Group | 2,367,353 | 4.60% | Form 13F, quarter ended March 31, 2026 |
| Rick E Winningham | 2,013,938 | 3.91% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| State Street | 1,297,323 | 2.52% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 1,258,497 | 2.44% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 51,515,000 shares outstanding, as reported by Theravance Biopharma, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Theravance Biopharma, Inc.'s shareholder meeting held June 12, 2026, in the 2025-2026 proxy season, 214 asset managers reported votes on at least one of its 8 ballot items in their SEC Form N-PX filings, covering 1,868 separate fund positions. On the most widely held item on that ballot — Approve the non-binding advisory resolution regarding the compensation of our named executive… — Theravance Biopharma, Inc.'s filing reports the proposal as approved, with 99.5% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Theravance Biopharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Theravance Biopharma, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Theravance Biopharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Theravance Biopharma, Inc. 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/theravance-biopharma-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.